Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry

DOI: https://doi.org/10.1007/s00401-024-02729-7

IF: 15.887

2024-05-19

Acta Neuropathologica

Abstract:Antibodies are essential research tools whose performance directly impacts research conclusions and reproducibility. Owing to its central role in Alzheimer's disease and other dementias, hundreds of distinct antibody clones have been developed against the microtubule-associated protein Tau and its multiple proteoforms. Despite this breadth of offer, limited understanding of their performance and poor antibody selectivity have hindered research progress. Here, we validate a large panel of Tau antibodies by Western blot (79 reagents) and immunohistochemistry (35 reagents). We address the reagents' ability to detect the target proteoform, selectivity, the impact of protein phosphorylation on antibody binding and performance in human brain samples. While most antibodies detected Tau at high levels, many failed to detect it at lower, endogenous levels. By WB, non-selective binding to other proteins affected over half of the antibodies tested, with several cross-reacting with the related MAP2 protein, whereas the "oligomeric Tau" T22 antibody reacted with monomeric Tau by WB, thus calling into question its specificity to Tau oligomers. Despite the presumption that "total" Tau antibodies are agnostic to post-translational modifications, we found that phosphorylation partially inhibits binding for many such antibodies, including the popular Tau-5 clone. We further combine high-sensitivity reagents, mass-spectrometry proteomics and cDNA sequencing to demonstrate that presumptive Tau "knockout" human cells continue to express residual protein arising through exon skipping, providing evidence of previously unappreciated gene plasticity. Finally, probing of human brain samples with a large panel of antibodies revealed the presence of C-term-truncated versions of all main Tau brain isoforms in both control and tauopathy donors. Ultimately, we identify a validated panel of Tau antibodies that can be employed in Western blotting and/or immunohistochemistry to reliably detect even low levels of Tau expression with high selectivity. This work represents an extensive resource that will enable the re-interpretation of published data, improve reproducibility in Tau research, and overall accelerate scientific progress.

pathology,neurosciences,clinical neurology

What problem does this paper attempt to address?

The paper aims to address the following issues: 1. **Antibody Performance Validation**: The paper validates a large number of Tau protein antibodies, particularly their performance in Western blot (WB) and immunohistochemistry (IHC). Through these experiments, the researchers aim to determine which antibodies can reliably detect different forms of Tau protein. 2. **Selectivity and Specificity**: The study evaluates the selectivity and specificity of the antibodies, especially against different phosphorylation states and other modified forms of Tau protein. Many antibodies can detect Tau at high expression levels but perform poorly at endogenous levels. 3. **Non-specific Binding**: The study found that more than half of the tested antibodies have issues with non-specific binding to other proteins, with some also cross-reacting with the related MAP2 protein. 4. **Effect of Phosphorylation on Binding**: Although it is generally believed that "total Tau" antibodies are insensitive to phosphorylation modifications, the study found that phosphorylation partially inhibits the binding ability of many such antibodies, including the commonly used Tau-5 clone. 5. **Expression in Knockout Cells**: Using high-sensitivity reagents, mass spectrometry, and cDNA sequencing, the study found that so-called Tau "knockout" human cells still exhibit residual Tau protein expression generated through exon skipping, revealing previously unrecognized genetic plasticity. 6. **Tau Isoforms in Human Brain Samples**: By analyzing human brain samples with a large number of antibody probes, the study discovered C-terminal truncated versions of all major Tau brain isoforms, present in both control and Tauopathy patients. Ultimately, this paper provides a set of validated Tau antibody resources that can reliably detect low levels of Tau expression in WB and IHC with high selectivity. This will help reinterpret published data, improve the reproducibility of Tau research, and accelerate scientific progress.

Identification of high-performing antibodies for the reliable detection of Tau proteoforms by Western blotting and immunohistochemistry

A guide to selecting high-performing antibodies for amyloid-beta precursor protein for use in Western Blot, immunoprecipitation and immunofluorescence

High-affinity antibodies specific to the core region of the tau protein exhibit diagnostic and therapeutic potential for Alzheimer's disease

Novel ultrasensitive immunoassay for the selective quantification of tau oligomers and related soluble aggregates

Generation of nanobodies with conformational specificity for tau oligomers that recognize tau aggregates from human Alzheimer's disease samples

The Prepared Tau Exon-Specific Antibodies Revealed Distinct Profiles of Tau in CSF of the Patients with Creutzfeldt-Jakob Disease.

Fully synthetic phosphorylated Tau181, Tau217, and Tau231 calibrators for Alzheimer's disease diagnosis

Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis

The identification of high-performing antibodies for Sequestosome-1 for use in Western blot, immunoprecipitation and immunofluorescence

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease

Development of a pan‐tau multivalent nanobody that binds tau aggregation motifs and recognizes pathological tau aggregates

Simultaneous Detection of Six Isoforms of Tau Protein in Human Cerebrospinal Fluid by Multidimensional Mass Spectrometry-Based Targeted Proteomics.

Functional Selection of Tau Oligomerization‐Inhibiting Aptamers

Optimal blood tau species for the detection of Alzheimer's disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study

Development and characterization of novel anti-acetylated tau monoclonal antibodies to probe pathogenic tau species in Alzheimer's disease

Identifying Optimal Blood Tau Epitopes for the Detection of Alzheimer’s Disease Neuropathology: An Immunoprecipitation Mass Spectrometry and Autopsy Study

Assessment of immunoprecipitation with subsequent immunoassays for the blood-based diagnosis of Alzheimer's disease

Conformation-selective tau monoclonal antibodies inhibit tau pathology in primary neurons and a mouse model of Alzheimer’s disease

A single-domain antibody for the detection of pathological Tau protein in the early stages of oligomerization

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease

Probe-dependent Proximity Profiling (ProPPr) Uncovers Similarities and Differences in Phospho-Tau-Associated Proteomes Between Tauopathies